Aastrom Biosciences ends drug trial, to cut half its workforce
March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.
The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.
The company has about 71 employees, according to Thomson Reuters data.
- U.S. forces carry out operation against al-Shabaab in Somalia
- Ukraine accuses Russia of 'undisguised aggression' as rebels advance |
- Marilyn Monroe sex film to be kept private |
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
- Fast-food workers to launch intensified protests across U.S.